[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"meningioma-atypical\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:meningioma-atypical":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100423331","frequency-and-clinical-phenotype-of-bap1-hereditary-predisposition-syndrome-100423331",false,"NCT04792463","Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome","Inclusion Criteria:\n\nPatients who meet any of the following criteria:\n\n1. Personal history of one cancer reported in BAP1 cancer predisposition syndrome and family history of at least two 1st or 2nd degree relatives with cancer reported in hereditary BAP1 cancer predisposition syndrome such as UM, CM, mesothelioma, RCC, cholangiocarcinoma, meningioma and hepatocellular carcinoma.\n2. Any patient with personal history of at least 2 cancers reported in hereditary BAP1 cancer predisposition syndrome.\n3. Any subject (affected or unaffected) with a documented BAP1 pathogenic\u002F likely pathogenic variant.\n4. Any patient with a cancer reported in BAP1 and a germline variant of uncertain significance.\n5. At risk relatives of a patient with documented BAP1 mutation.\n\nExclusion Criteria:\n\n* Study material including consent forms are currently only available in English so non-English speaking subjects are excluding",true,"ALL",{"count":18,"type":19},500,"ESTIMATED","OBSERVATIONAL","This research will have a significant impact on the overall management of those cancer patients and their family members who are at risk for hereditary cancer due to germline inactivation of BAP1. Our study will ultimately facilitate the development of novel screening, prevention and treatment strategies for these individuals with the syndrome. Because the vast majority of UM develop in pre-existing nevi, characterization of individuals at high risk for development of UM will allow closer screening and earlier intervention which would improve the treatment outcome not only for retaining vision but also for overall survival. Similarly in patients with germline BAP1 mutation CM develops in premalignant atypical melanocytic lesions and careful follow up of these patients will improve the outcome of their disease. In addition this study could have impact on the management of patients with personal and\u002For family history of several other cancers reported in patients with germline BAP1 mutation such as mesothelioma, renal cell carcinoma, cholangiocarcinoma, hepatocellular carcinoma, meningioma and basal cell carcinoma.",[23,24,25,26,27,28,29,30],"Uveal Melanoma","Cutaneous Melanoma","BAP1 Gene Mutation","Renal Cell Carcinoma","Mesothelioma","Hepatocellular Carcinoma","Cholangiocarcinoma","Meningioma Atypical","RECRUITING","2026-03-05",{"date":34,"type":35},"2026-03-09","ACTUAL",{"date":37,"type":35},"2015-03-03",{"date":39,"type":19},"2026-07-01",{"name":41,"class":42},"Mohamed Abdel-Rahman","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":43},"100500190","predictive-factors-for-survival-in-aggressive-meningiomas-100500190","NCT05793034","Predictive Factors for Survival in Aggressive Meningiomas","Analysis of Predictive Factors for Overall and Progression-free Survival After Neurosurgery for Atypical or Anaplastic Meningioma","23Men","Inclusion Criteria:\n\n1. Patient operated for atypical (grade 2) meningioma; or\n2. Patient operated for anaplastic (grade 3) meningioma;\n3. Timeframe for surgery, 1999-2019\n\nExclusion criteria\n\n1\\) Patient lost at follow-up","18 Years",{"count":54,"type":19},250,"INTERVENTIONAL",[57],"NA","The investigators plan to collect clinical and molecular data, including ICH, PCR, NGS and methylome, from patients operated on for grade 2 or grade 3 meningioma. The purpose of the study is to identify reliable and easy-to-assess predictive factors for recurrence and survival after surgery.",[60,30,61],"Meningioma","Anaplastic Meningioma","2025-03-11",{"date":64,"type":35},"2025-03-13",{"date":66,"type":35},"2021-01-07",{"date":68,"type":19},"2027-01-07",{"name":70,"class":42},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":55,"phases":81,"briefSummary":82,"conditions":83,"keywords":87,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100372312","efficacy-of-postoperative-radiotherapy-for-atypical-meningioma-without-venous-sinus-invasion-after-gross-total-resection-100372312","NCT04127760","Efficacy of Postoperative Radiotherapy for Atypical Meningioma Without Venous Sinus Invasion After Gross-total Resection","A Multicenter Randomized Controlled Trial of the Efficacy of Postoperative Radiotherapy for Atypical Meningioma Without Venous Sinus Invasion After Gross-total Resection","Inclusion Criteria:\n\n* Patients who underwent gross total resection at each center and were diagnosed as atypical meningioma (WHO class II) according to the WHO 2016 diagnostic criteria.\n* Gross total resection was defined as modified Simpson 1-3 and confirmed by postoperative magnetic resonance imaging.\n\nExclusion Criteria:\n\n* age less than 18 years old or older than 70 years\n* meningioma recurrence\n* patients had previous radiotherapy\n* multiple meningioma\n* optic nerve sheath meningioma or other extracranial meningioma\n* tumor involving venous sinus\n* ECOG score ≥ 2 points\n* preoperative ASA grade ≥ 3\n* previous or current malignant tumors\n* pregnant or lactating women\n* Patients with Gd-DTPA allergies, spatial claustrophobia or pacemaker implantation that can not be conducted constract-enhanced head magnetic resonance examination\n* patients who were unable to obtain informed consent or refused to participate in the study.","70 Years",{"count":80,"type":19},140,[57],"Postoperative adjuvant radiotherapy is a key component of comprehensive treatment of meningioma. However, for atypical meningioma after total resection, there is still a huge controversy in patients who need adjuvant radiotherapy after surgery.\n\nMany scholars have focused on this problem and carried out some small-scale retrospective studies, but they have contradictory results. Some of the studies found that postoperative adjuvant radiotherapy could not improve the prognosis of patients, but was questioned because the sample size was too small, resulting in insignificant results, while other studies found that postoperative adjuvant radiotherapy can improve progression free survival. A study based on the National Cancer Database found that postoperative adjuvant radiotherapy and gross tumor resection are associated with a good prognosis. A recent meta-analysis enrolled a total of 757 patients and found that postoperative adjuvant radiotherapy reduced the risk of tumor recurrence but did not improve survival time. Our team reviewed the meningioma data in the SEER database and conducted a study previously. The study found that postoperative adjuvant radiotherapy did not improve the overall survival of these patients. The relevant research results were recently published in Frontiers in oncology. We further reviewed and summarized the single-center data of our hospital and found that postoperative adjuvant radiotherapy could not improve the progression free survival and overall survival of patients. Besides, we also performed a meta-analysis and found that postoperative adjuvant radiotherapy had a trend to improve progression-free survival, but there was no statistical difference.\n\nBecause there are many deficiencies in previous researches, and the research results are also contradictory, it is still unclear whether patients with atypical meningioma who have undergone gross total resection can benefit from postoperative adjuvant radiotherapy. Further high quality clinical trials is still needed to be conducted in order to guide the postoperative care of patients. Therefore, we intend to conduct this multicenter randomized controlled trial to determine the value of postoperative adjuvant radiotherapy in patients with atypical meningioma who underwent gross total resection.",[30,84,85,86],"Radiotherapy","Progression-Free Survival","Adverse Effect of Radiation Therapy",[30,88],"radiotherapy","NOT_YET_RECRUITING","2019-10-15",{"date":92,"type":35},"2019-10-16",{"date":94,"type":19},"2020-01-01",{"date":96,"type":19},"2033-01-01",{"name":98,"class":42},"Second Affiliated Hospital, School of Medicine, Zhejiang University"]